請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50100完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李明學 | |
| dc.contributor.author | Yung-Hsun Kang | en |
| dc.contributor.author | 康詠洵 | zh_TW |
| dc.date.accessioned | 2021-06-15T12:29:43Z | - |
| dc.date.available | 2019-08-26 | |
| dc.date.copyright | 2016-08-26 | |
| dc.date.issued | 2016 | |
| dc.date.submitted | 2016-08-05 | |
| dc.identifier.citation | 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29.
2. http://www.mohw.gov.tw/news/531349778. 3. Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol. 2007;9 Suppl 1:S3-8. 4. Kasper S, Cookson MS. Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am. 2006 May;33(2):201-10, vii. 5. McPhaul MJ. Mechanisms of prostate cancer progression to androgen independence. Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):373-88. 6. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013 Dec 5;32(49):5501-11. 7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646-74. 8. Duffy MJ. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis. 1992 May;10(3):145-55. 9. Lu P, Takai K, Weaver VM, Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol. 2011 Dec;3(12). 10. Hart CA, Scott LJ, Bagley S, Bryden AA, Clarke NW, Lang SH. Role of proteolytic enzymes in human prostate bone metastasis formation: in vivo and in vitro studies. Br J Cancer. 2002 Apr 8;86(7):1136-42. 11. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des. 2004;10(1):39-49. 12. Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem. 2004 Jul;37(7):541-8. 13. Conese M, Blasi F. The urokinase/urokinase-receptor system and cancer invasion. Baillieres Clin Haematol. 1995 Jun;8(2):365-89. 14. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997 Jul 3;72(1):1-22. 15. Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays. 1993 Feb;15(2):105-11. 16. Dano K, Behrendt N, Hoyer-Hansen G, Johnsen M, Lund LR, Ploug M, et al. Plasminogen activation and cancer. Thromb Haemost. 2005 Apr;93(4):676-81. 17. van Zijl F, Krupitza G, Mikulits W. Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res. 2011 Jul-Oct;728(1-2):23-34. 18. Duffy MJ, Maguire TM, McDermott EW, O'Higgins N. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol. 1999 Jun;71(2):130-5. 19. Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem. 2002 Aug;48(8):1194-7. 20. Duffy MJ. Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers. Biochem Soc Trans. 2002 Apr;30(2):207-10. 21. Verma RP, Hansch C. Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorg Med Chem. 2007 Mar 15;15(6):2223-68. 22. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463-516. 23. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003 May 2;92(8):827-39. 24. Fink K, Boratynski J. [The role of metalloproteinases in modification of extracellular matrix in invasive tumor growth, metastasis and angiogenesis]. Postepy Hig Med Dosw (Online). 2012;66:609-28. 25. Johansson N, Ahonen M, Kahari VM. Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci. 2000 Jan 20;57(1):5-15. 26. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, et al. An essential role for ectodomain shedding in mammalian development. Science. 1998 Nov 13;282(5392):1281-4. 27. Rebustini IT, Myers C, Lassiter KS, Surmak A, Szabova L, Holmbeck K, et al. MT2-MMP-dependent release of collagen IV NC1 domains regulates submandibular gland branching morphogenesis. Dev Cell. 2009 Oct;17(4):482-93. 28. Orlichenko LS, Radisky DC. Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin Exp Metastasis. 2008;25(6):593-600. 29. Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):201-12. 30. Tester AM, Ruangpanit N, Anderson RL, Thompson EW. MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits. Clin Exp Metastasis. 2000;18(7):553-60. 31. Roomi MW, Monterrey JC, Kalinovsky T, Rath M, Niedzwiecki A. Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep. 2009 May;21(5):1323-33. 32. Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 2005 May 25;1755(1):37-69. 33. Zhang XY, Hong BF, Chen GF, Lu YL, Zhong M. [Significance of MMP2 and MMP9 expression in prostate cancer]. Zhonghua Nan Ke Xue. 2005 May;11(5):359-61, 64. 34. Shi YE, Torri J, Yieh L, Wellstein A, Lippman ME, Dickson RB. Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res. 1993 Mar 15;53(6):1409-15. 35. Lin CY, Wang JK, Torri J, Dou L, Sang QA, Dickson RB. Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization. J Biol Chem. 1997 Apr 4;272(14):9147-52. 36. Netzel-Arnett S, Hooper JD, Szabo R, Madison EL, Quigley JP, Bugge TH, et al. Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):237-58. 37. Oberst MD, Williams CA, Dickson RB, Johnson MD, Lin CY. The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. J Biol Chem. 2003 Jul 18;278(29):26773-9. 38. Oberst MD, Chen LY, Kiyomiya K, Williams CA, Lee MS, Johnson MD, et al. HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease. Am J Physiol Cell Physiol. 2005 Aug;289(2):C462-70. 39. List K, Bugge TH, Szabo R. Matriptase: potent proteolysis on the cell surface. Mol Med. 2006 Jan-Mar;12(1-3):1-7. 40. Benaud C, Dickson RB, Lin CY. Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur J Biochem. 2001 Mar;268(5):1439-47. 41. List K, Szabo R, Molinolo A, Nielsen BS, Bugge TH. Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis. Am J Pathol. 2006 May;168(5):1513-25. 42. Tanimoto H, Underwood LJ, Wang Y, Shigemasa K, Parmley TH, O'Brien TJ. Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention. Tumour Biol. 2001 Mar-Apr;22(2):104-14. 43. Takeuchi T, Shuman MA, Craik CS. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11054-61. 44. Oberst M, Anders J, Xie B, Singh B, Ossandon M, Johnson M, et al. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol. 2001 Apr;158(4):1301-11. 45. List K, Kosa P, Szabo R, Bey AL, Wang CB, Molinolo A, et al. Epithelial integrity is maintained by a matriptase-dependent proteolytic pathway. Am J Pathol. 2009 Oct;175(4):1453-63. 46. Smith FJ, Irvine AD, Terron-Kwiatkowski A, Sandilands A, Campbell LE, Zhao Y, et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet. 2006 Mar;38(3):337-42. 47. Presland RB, Boggess D, Lewis SP, Hull C, Fleckman P, Sundberg JP. Loss of normal profilaggrin and filaggrin in flaky tail (ft/ft) mice: an animal model for the filaggrin-deficient skin disease ichthyosis vulgaris. J Invest Dermatol. 2000 Dec;115(6):1072-81. 48. Lee JW, Yong Song S, Choi JJ, Lee SJ, Kim BG, Park CS, et al. Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. Hum Pathol. 2005 Jun;36(6):626-33. 49. Riddick AC, Shukla CJ, Pennington CJ, Bass R, Nuttall RK, Hogan A, et al. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer. 2005 Jun 20;92(12):2171-80. 50. Benaud CM, Oberst M, Dickson RB, Lin CY. Deregulated activation of matriptase in breast cancer cells. Clin Exp Metastasis. 2002;19(7):639-49. 51. Forbs D, Thiel S, Stella MC, Sturzebecher A, Schweinitz A, Steinmetzer T, et al. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int J Oncol. 2005 Oct;27(4):1061-70. 52. Vogel LK, Saebo M, Skjelbred CF, Abell K, Pedersen ED, Vogel U, et al. The ratio of Matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals. BMC Cancer. 2006;6:176. 53. Zeng L, Cao J, Zhang X. Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract. World J Gastroenterol. 2005 Oct 21;11(39):6202-7. 54. Johnson MD, Oberst MD, Lin CY, Dickson RB. Possible role of matriptase in the diagnosis of ovarian cancer. Expert Rev Mol Diagn. 2003 May;3(3):331-8. 55. Jin JS, Chen A, Hsieh DS, Yao CW, Cheng MF, Lin YF. Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters. Int J Surg Pathol. 2006 Jan;14(1):65-72. 56. Galkin AV, Mullen L, Fox WD, Brown J, Duncan D, Moreno O, et al. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate. 2004 Nov 1;61(3):228-35. 57. Tsui KH, Chang PL, Feng TH, Chung LC, Sung HC, Juang HH. Evaluating the function of matriptase and N-acetylglucosaminyltransferase V in prostate cancer metastasis. Anticancer Res. 2008 Jul-Aug;28(4A):1993-9. 58. Ko CJ, Huang CC, Lin HY, Juan CP, Lan SW, Shyu HY, et al. Androgen-Induced TMPRSS2 Activates Matriptase and Promotes Extracellular Matrix Degradation, Prostate Cancer Cell Invasion, Tumor Growth, and Metastasis. Cancer Res. 2015 Jul 15;75(14):2949-60. 59. Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, et al. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):217-27. 60. Benaud C, Oberst M, Hobson JP, Spiegel S, Dickson RB, Lin CY. Sphingosine 1-phosphate, present in serum-derived lipoproteins, activates matriptase. J Biol Chem. 2002 Mar 22;277(12):10539-46. 61. Wu SR, Cheng TS, Chen WC, Shyu HY, Ko CJ, Huang HP, et al. Matriptase is involved in ErbB-2-induced prostate cancer cell invasion. Am J Pathol. 2010 Dec;177(6):3145-58. 62. Satomi S, Yamasaki Y, Tsuzuki S, Hitomi Y, Iwanaga T, Fushiki T. A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover. Biochem Biophys Res Commun. 2001 Oct 5;287(4):995-1002. 63. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem. 2000 Nov 24;275(47):36720-5. 64. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem. 2000 Aug 25;275(34):26333-42. 65. Jin X, Yagi M, Akiyama N, Hirosaki T, Higashi S, Lin CY, et al. Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis. Cancer Sci. 2006 Dec;97(12):1327-34. 66. Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer. 2011 Jan;11(1):23-34. 67. Cuypers HT, Selten G, Quint W, Zijlstra M, Maandag ER, Boelens W, et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell. 1984 May;37(1):141-50. 68. Liang H, Hittelman W, Nagarajan L. Ubiquitous expression and cell cycle regulation of the protein kinase PIM-1. Arch Biochem Biophys. 1996 Jun 15;330(2):259-65. 69. http://www.proteinatlas.org/ENSG00000137193-PIM1/tissue. 70. Saris CJ, Domen J, Berns A. The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J. 1991 Mar;10(3):655-64. 71. Qian KC, Wang L, Hickey ER, Studts J, Barringer K, Peng C, et al. Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem. 2005 Feb 18;280(7):6130-7. 72. Wang Z, Bhattacharya N, Weaver M, Petersen K, Meyer M, Gapter L, et al. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci. 2001 Dec;2(3):167-79. 73. Krumenacker JS, Narang VS, Buckley DJ, Buckley AR. Prolactin signaling to pim-1 expression: a role for phosphatidylinositol 3-kinase. J Neuroimmunol. 2001 Feb 15;113(2):249-59. 74. Miura O, Miura Y, Nakamura N, Quelle FW, Witthuhn BA, Ihle JN, et al. Induction of tyrosine phosphorylation of Vav and expression of Pim-1 correlates with Jak2-mediated growth signaling from the erythropoietin receptor. Blood. 1994 Dec 15;84(12):4135-41. 75. Zhu N, Ramirez LM, Lee RL, Magnuson NS, Bishop GA, Gold MR. CD40 signaling in B cells regulates the expression of the Pim-1 kinase via the NF-kappa B pathway. J Immunol. 2002 Jan 15;168(2):744-54. 76. Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, Kuchino Y. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem. 1999 Jun 25;274(26):18659-66. 77. Bachmann M, Kosan C, Xing PX, Montenarh M, Hoffmann I, Moroy T. The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C. Int J Biochem Cell Biol. 2006 Mar;38(3):430-43. 78. Wang Z, Bhattacharya N, Mixter PF, Wei W, Sedivy J, Magnuson NS. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta. 2002 Dec 16;1593(1):45-55. 79. Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res. 2008 Jul 1;68(13):5076-85. 80. Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett. 2004 Jul 30;571(1-3):43-9. 81. Amson R, Sigaux F, Przedborski S, Flandrin G, Givol D, Telerman A. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci U S A. 1989 Nov;86(22):8857-61. 82. Guo S, Mao X, Chen J, Huang B, Jin C, Xu Z, et al. Overexpression of Pim-1 in bladder cancer. J Exp Clin Cancer Res. 2010;29:161. 83. Yan B, Yau EX, Samanta S, Ong CW, Yong KJ, Ng LK, et al. Clinical and therapeutic relevance of PIM1 kinase in gastric cancer. Gastric Cancer. 2012 Apr;15(2):188-97. 84. Beier UH, Weise JB, Laudien M, Sauerwein H, Gorogh T. Overexpression of Pim-1 in head and neck squamous cell carcinomas. Int J Oncol. 2007 Jun;30(6):1381-7. 85. Valdman A, Fang X, Pang ST, Ekman P, Egevad L. Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer. Prostate. 2004 Sep 1;60(4):367-71. 86. Cibull TL, Jones TD, Li L, Eble JN, Ann Baldridge L, Malott SR, et al. Overexpression of Pim-1 during progression of prostatic adenocarcinoma. J Clin Pathol. 2006 Mar;59(3):285-8. 87. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, et al. Delineation of prognostic biomarkers in prostate cancer. Nature. 2001 Aug 23;412(6849):822-6. 88. Jiang R, Wang X, Jin Z, Li K. Association of Nuclear PIM1 Expression with Lymph Node Metastasis and Poor Prognosis in Patients with Lung Adenocarcinoma and Squamous Cell Carcinoma. J Cancer. 2016;7(3):324-34. 89. Santio NM, Eerola SK, Paatero I, Yli-Kauhaluoma J, Anizon F, Moreau P, et al. Pim Kinases Promote Migration and Metastatic Growth of Prostate Cancer Xenografts. PLoS One. 2015;10(6):e0130340. 90. Rang Z, Yang G, Wang YW, Cui F. miR-542-3p suppresses invasion and metastasis by targeting the proto-oncogene serine/threonine protein kinase, PIM1, in melanoma. Biochem Biophys Res Commun. 2016 May 27;474(2):315-20. 91. Magnuson NS, Wang Z, Ding G, Reeves R. Why target PIM1 for cancer diagnosis and treatment? Future Oncol. 2010 Sep;6(9):1461-78. 92. Fathi AT, Arowojolu O, Swinnen I, Sato T, Rajkhowa T, Small D, et al. A potential therapeutic target for FLT3-ITD AML: PIM1 kinase. Leuk Res. 2012 Feb;36(2):224-31. 93. Xie Y, Bayakhmetov S. PIM1 kinase as a promise of targeted therapy in prostate cancer stem cells. Mol Clin Oncol. 2016 Jan;4(1):13-7. 94. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, et al. LNCaP model of human prostatic carcinoma. Cancer Res. 1983 Apr;43(4):1809-18. 95. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer. 1978 Mar 15;21(3):274-81. 96. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979 Jul;17(1):16-23. 97. Meeker TC, Nagarajan L, ar-Rushdi A, Croce CM. Cloning and characterization of the human PIM-1 gene: a putative oncogene related to the protein kinases. J Cell Biochem. 1987 Oct;35(2):105-12. 98. Ha S, Iqbal NJ, Mita P, Ruoff R, Gerald WL, Lepor H, et al. Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer. Oncogene. 2013 Aug 22;32(34):3992-4000. 99. Linn DE, Yang X, Xie Y, Alfano A, Deshmukh D, Wang X, et al. Differential regulation of androgen receptor by PIM-1 kinases via phosphorylation-dependent recruitment of distinct ubiquitin E3 ligases. J Biol Chem. 2012 Jun 29;287(27):22959-68. 100. Chiocchetti A, Gibello L, Carando A, Aspesi A, Secco P, Garelli E, et al. Interactions between RPS19, mutated in Diamond-Blackfan anemia, and the PIM-1 oncoprotein. Haematologica. 2005 Nov;90(11):1453-62. 101. Legrand C, Polette M, Tournier JM, de Bentzmann S, Huet E, Monteau M, et al. uPA/plasmin system-mediated MMP-9 activation is implicated in bronchial epithelial cell migration. Exp Cell Res. 2001 Apr 1;264(2):326-36. 102. Shay KP, Wang Z, Xing PX, McKenzie IF, Magnuson NS. Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway. Mol Cancer Res. 2005 Mar;3(3):170-81. 103. Santio NM, Salmela M, Arola H, Eerola SK, Heino J, Rainio EM, et al. The PIM1 kinase promotes prostate cancer cell migration and adhesion via multiple signalling pathways. Exp Cell Res. 2016 Mar 15;342(2):113-24. 104. Wang J, Anderson PD, Luo W, Gius D, Roh M, Abdulkadir SA. Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells. Oncogene. 2012 Apr 5;31(14):1794-803. 105. Kim J, Roh M, Abdulkadir SA. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity. BMC Cancer. 2010;10:248. 106. Hu XF, Li J, Vandervalk S, Wang Z, Magnuson NS, Xing PX. PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. J Clin Invest. 2009 Feb;119(2):362-75. 107. Adam M, Pogacic V, Bendit M, Chappuis R, Nawijn MC, Duyster J, et al. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL. Cancer Res. 2006 Apr 1;66(7):3828-35. 108. Blanco-Aparicio C, Collazo AM, Oyarzabal J, Leal JF, Albaran MI, Lima FR, et al. Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. Cancer Lett. 2011 Jan 28;300(2):145-53. 109. Draptchinskaia N, Gustavsson P, Andersson B, Pettersson M, Willig TN, Dianzani I, et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet. 1999 Feb;21(2):169-75. 110. Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity. 1999 Dec;11(6):709-19. 111. Wang J, Kim J, Roh M, Franco OE, Hayward SW, Wills ML, et al. Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene. 2010 Apr 29;29(17):2477-87. 112. Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest. 2005 Oct;115(10):2618-24. 113. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997 Oct 17;91(2):231-41. 114. Muraski JA, Rota M, Misao Y, Fransioli J, Cottage C, Gude N, et al. Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med. 2007 Dec;13(12):1467-75. 115. Cen B, Mahajan S, Wang W, Kraft AS. Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Res. 2013 Jun 1;73(11):3402-11. 116. Cen B, Xiong Y, Song JH, Mahajan S, DuPont R, McEachern K, et al. The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling. Mol Cell Biol. 2014 Jul;34(13):2517-32. 117. Patel MB, Pothula SP, Xu Z, Lee AK, Goldstein D, Pirola RC, et al. The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer. Carcinogenesis. 2014 Aug;35(8):1891-900. 118. Lee KH, Choi EY, Hyun MS, Jang BI, Kim TN, Kim SW, et al. Hepatocyte growth factor/c-met signaling in regulating urokinase plasminogen activator in human stomach cancer: A potential therapeutic target for human stomach cancer. Korean J Intern Med. 2006 Mar;21(1):20-7. 119. Xie Y, Xu K, Dai B, Guo Z, Jiang T, Chen H, et al. The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene. 2006 Jan 5;25(1):70-8. 120. Mumenthaler SM, Ng PY, Hodge A, Bearss D, Berk G, Kanekal S, et al. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther. 2009 Oct;8(10):2882-93. 121. van der Poel HG, Zevenhoven J, Bergman AM. Pim1 regulates androgen-dependent survival signaling in prostate cancer cells. Urol Int. 2010;84(2):212-20. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50100 | - |
| dc.description.abstract | 晚期攝護腺（前列腺）癌的患者預後往往極差，並且這類的癌細胞具有很強的侵襲、轉移能力。然而，這些癌細胞如何轉移的詳細機制目前仍然不是非常清楚。目前已知 PIM 激酶在晚期攝護腺癌中會大量表現，並且也有人將它視為預測攝護腺癌的指標之一。PIM1 激酶已知可以參與促進攝護腺癌生存、細胞增生以及細胞癌化的過程中，然而PIM1 如何、是否可以促使攝護腺癌細胞移動和轉移能力增加仍然需要更多的探討。在本篇研究中，我發現PIM1 表現量和攝護腺癌侵襲能力有正相關的關聯性，除此之外，抑制PIM1 表現量或利用他的抑制劑（SGI-1776）抑制其活性都可以有效抑制攝護腺癌細胞（DU145 & PC3）的移動能力。然而過度表達PIM1 可以顯著的提升人類胚胎腎臟細胞（HEK293T）以及攝護腺癌細胞（LNCaP）移動能力。此外，研究結果顯示鑲嵌於膜上的絲氨酸蛋白酶 Matriptase活性會受到PIM1 的影響。當抑制了Matriptase的表現量之下，也會抑制PIM1促使攝護腺癌細胞侵襲能力增加的這個現象。因此，綜合本篇的結果，暗示著PIM1 可以促使Matriptase 活化進而導致攝護腺癌細胞侵襲能力增加，並且可以作為未來治療攝護腺癌的藥物設計的重要目標。 | zh_TW |
| dc.description.abstract | Advanced prostate cancer (PCa) is poor prognosis with high metastasis. However, the molecular mechanism how advanced PCa acquires invasive and metastatic potential is still unclear. Several lines of evidences have shown that PIM kinase is up-regulated in advanced PCa and suggested as a prognostic biomarker for the cancer. In spite of the involvement of PIM1 in PCa cell survival, proliferation and tumorigenicity, whether PIM1 can also promote PCa cell motility and metastasis is still elusive. In this study, I found that the expression level of PIM1 was correlated with the capability of PCa cell invasion. Moreover, PIM1 silencing or treating with PIM1 inhibitor (SGI-1776) could inhibit PCa DU145 and PC3 cell invasion, while overexpression of PIM1 significantly increase the invasion capability of HEK293T and LNCaP cells. In addition, the results further showed that the activity of a membrane-anchored serine protease matriptase was affected by PIM1. Furthermore, matriptase silencing reduced PIM1-induced PCa cell invasion. Thus, the data together indicate that PIM1 can induce matriptase activation, leading to PCa cell invasion, and may serve as an important target for drug development for prostate cancer treatment. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T12:29:43Z (GMT). No. of bitstreams: 1 ntu-105-R03442005-1.pdf: 10841981 bytes, checksum: 74f4271bb32d6ce2ff513f73970c31f3 (MD5) Previous issue date: 2016 | en |
| dc.description.tableofcontents | 致謝 ......................................................................................................................... i
摘要 ....................................................................................................................... iii Abstract ................................................................................................................ iv Chapter 1. Introduction ........................................................................................... 1 Prostate cancer ...................................................................................................... 2 Cancer development and metastasis ..................................................................... 3 Proteolytic enzymes .............................................................................................. 4 1.1.1 Urokinase plasminogen activator (uPA)........................................................... 4 1.1.2 Matrix metalloproteinase (MMP) ..................................................................... 5 1.1.3 Matriptase ................................................................................................. 6-10 PIM1 (Proviral insertion site for Molony murine leukemia virus -1) -------------10-11 Research motivation ..............................................................................................12 Chapter 2. Material and Methods ..........................................................................13 2.1 Materials ..........................................................................................................14 2.1.1 Cell lines ........................................................................................................14 2.1.2 Antibodies .................................................................................................... 15 2.1.3 Enzymes ........................................................................................................15 2.1.4 Reagents ..................................................................................................16-18 2.1.5 Instruments ...................................................................................................18 2.2 Methods...........................................................................................................18 2.2.1 Cell culture ....................................................................................................18 2.2.2 Plasmid construction ..............................................................................19-20 2.2.3 Transfection ................................................................................................21 2.2.4 shRNA preparation and infection ...........................................................21-22 2.2.5 Cell cytotoxicity assay ...........................................................................22-23 2.2.6 Cell proliferation assay................................................................................ 23 2.2.7 Transwell invasion/migration assay .......................................................23-24 2.2.8 RNA extraction and quantitative real-time PCR (qRT-PCR) ....................24-27 2.2.9 Western blotting ....................................................................................27-28 2.2.10 Zymography assay ...............................................................................28-30 Chapter 3. Results ................................................................................................31 3.1 Correlation of PIM1 and prostate cancer cell motility ......................................32 3.2 Correlation of PIM1 and androgen dependency of prostate cancer ..........32-33 3.3 Role of PIM1 in prostate cancer cell motility....................................................34 3.4 Effect of PIM1 inhibitor (SGI-1776) on prostate cancer cell invasion..........34-35 3.5 Effect of PIM1 overexpression and its kinase activity on cell invasion........35-36 3.6 Role of PIM1 knockdown in metastasis-related proteases..........................36-37 3.7 Role of PIM1 overexpression in metastasis-related proteases....................38-39 3.8 PIM1 promote prostate cancer cell invasion through matriptase......................40 3.9 Matriptase acted as an effector for PIM1-induced prostate cancer cell invasion ........................................................................................................................40-41 3.10 Summary ......................................................................................................41 Chapter 4. Discussion....................................................................................42-47 Chapter 5. Figures......................................................................................... 48-74 Chapter 6. References ...................................................................................76-86 | |
| dc.language.iso | en | |
| dc.subject | PIM1 | zh_TW |
| dc.subject | 前列腺癌 | zh_TW |
| dc.subject | 侵襲能力 | zh_TW |
| dc.subject | 轉移 | zh_TW |
| dc.subject | Matriptase | zh_TW |
| dc.subject | 前列腺癌 | zh_TW |
| dc.subject | PIM1 | zh_TW |
| dc.subject | 侵襲能力 | zh_TW |
| dc.subject | 轉移 | zh_TW |
| dc.subject | Matriptase | zh_TW |
| dc.subject | Prostate cancer | en |
| dc.subject | Matriptase | en |
| dc.subject | Invasion | en |
| dc.subject | PIM1 | en |
| dc.subject | Prostate cancer | en |
| dc.subject | Matriptase | en |
| dc.subject | Invasion | en |
| dc.subject | PIM1 | en |
| dc.title | PIM1 在前列腺癌移動能力中扮演的角色 | zh_TW |
| dc.title | Role of PIM1 in prostate cancer cell motility | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 104-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 華國泰,顧記華,曾秀如 | |
| dc.subject.keyword | 前列腺癌,PIM1,侵襲能力,轉移,Matriptase, | zh_TW |
| dc.subject.keyword | Prostate cancer,PIM1,Invasion,Matriptase, | en |
| dc.relation.page | 86 | |
| dc.identifier.doi | 10.6342/NTU201602004 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2016-08-05 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
| 顯示於系所單位： | 生物化學暨分子生物學科研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-105-1.pdf 未授權公開取用 | 10.59 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。